White fat stores excess energy, while brown and beige fat dissipate energy as heat 1 . These 35 thermogenic adipose tissues markedly improve glucose and lipid homeostasis in mouse 36 models, though the extent to which brown adipose tissue (BAT) influences metabolic and 37 cardiovascular disease in humans is unclear 2,3,4 . Here, we categorized 139,224 18 F-FDG 38 PET/CT scans from 53,475 patients by presence or absence of BAT and used propensity score 39 matching to assemble a study cohort. Individuals with BAT showed lower prevalences of 40 cardiometabolic diseases. Additionally, BAT independently correlated with lower odds of type II 41 diabetes, coronary artery disease and congestive heart failure. These findings were supported 42 by improved glucose, triglyceride and high-density lipoprotein values. The effects of BAT were 43 more pronounced in overweight and obesity, indicating that BAT can offset the deleterious 44 effects of obesity. Strikingly, we also found lower rates of hypertension among patients with 45
addition to highlighting a role for BAT in promoting overall cardiometabolic health, this study 48 reveals a new link between thermogenic adipose tissue and blood pressure regulation. 49
Main 50
As early as 2003, reports described increased uptake of the labeled glucose analogue 51
Propensity score matching (PSM) allows for pairing of subjects with and without brown 84 fat, while accounting for covariates that predict the likelihood of having brown fat. We used PSM 85
to generate a study cohort without brown fat (N = 5,070), matching the individuals with brown fat 86 based on sex, age, BMI and outdoor temperature at the time of the index scan (Fig. 1h) . This 87 resulting study cohort was balanced across the aforementioned variables (Tab. 1; Extended 88 Data Fig. 3) . 89
Individuals with brown fat showed significantly lower prevalence of type II diabetes (4.6 90 vs. 9.1%, P<0.0001) and dyslipidemia (18.9 vs. 20.6%, P=0.0318). This protective effect was 91 also seen for cardiovascular disease, including atrial fibrillation/flutter (2.8 vs. 3.7%, P=0.0071), 92 coronary artery disease (3.1 vs. 5.0%, P<0.0001), cerebrovascular disease (2.1 vs. 3.1%, 93 P=0.0011), congestive heart failure (1.0 vs. 2.1%, P<0.0001) and hypertension (26.7 vs. 29.6%, 94 P=0.0003) ( Fig. 2a) . 95
Cancer-associated characteristics such as cachexia, cancer type and stage have 96 previously been associated with differences in brown fat prevalence on 18 F-FDG PET/CT, as 97 has the use of beta-blocker drugs 11, 17, 18, 19 . These associations were also observed in our study 98 (Extended Data Table 3 and Table 1 ). We used logistic regression analysis, adjusted for 99 cancer site, cancer stage, and beta-blocker use, and demographic variables (including race, 100 ethnicity, smoking status) to determine whether brown fat independently correlated with 101 cardiometabolic disease. Multivariable logistic regression analysis identified brown fat as an 102 independent negative predictor of type II diabetes (OR=0.46; 95% CI=0.39-0.55; P<0.0001), 103 coronary artery disease (OR=0.63; 95% CI=0.50-0.79; P<0.0001), congestive heart failure 104 (OR=0.56; 95% CI=0.40-0.80; P=0.0012) and hypertension (OR= 0.88; 95% CI=0.79-0.97; 105 P=0.0130) ( Fig. 2b and Extended Data Table 4) . 106
Next, we stratified these data by BMI to determine whether the association between 107 brown fat and improved cardiometabolic health was retained in overweight and obese 108 individuals. As the prevalence of metabolic and cardiovascular disease increased with higher 109 BMI, this effect was mitigated in individuals with brown fat (Fig. 2c) . The benefit associated with 110 brown fat was most striking for type II diabetes and coronary artery disease. For example, the 111 prevalence of type II diabetes in individuals with BMI > 30 kg/m 2 and brown fat was less than 112 half of the prevalence in obese individuals without brown fat (7.5 vs. 19.1%, P<0.0001). 113
Significantly lower prevalences of hypertension (39.9 vs. 47.0%, P=0.0020) and congestive 114 heart failure (1.1 vs. 2.9%, P=0.0060) were also observed in individuals with obesity and brown 115 fat. Using the multivariable logistic regression model described above, we confirmed that brown 116 fat was independently associated with the observed decrease in cardiometabolic disease 117 prevalence in obese individuals (Fig 2c) . 118
Next, we analyzed available laboratory values in temporal vicinity to the index scan to 119 further characterize the metabolic profile of the cohort. We noted distinct improvements in 120 glucose (91.7 vs. 95.1 mg/dl, P<0.0001), triglycerides (122.4 vs. 148.4 mg/dl, P=0.0006), and 121 HDL levels (56.4 vs. 52.2 mg/dl, P=0.0001) in individuals with brown fat, while there were no 122 differences for LDL (112.1 vs. 110.3 mg/dl, P=0.4406) and total cholesterol (192.3 vs. 188.6 123 mg/dl, P=0.1492) ( Fig. 2d and Extended Data Table 5 ). By stratifying laboratory values by 124 BMI, we found that changes in fasting blood glucose and triglycerides associated with elevated 125 BMI were offset in individuals with brown fat, and HDL levels were higher across all BMI 126 categories in individuals with brown fat (Fig. 2d ). There were no apparent differences in Data Table 5 ). However, both leukocyte (6.2 vs. 6.8 10 9 cells/L, 130 P<0.0001) and platelet counts (250 vs. 260 10 9 cells/L, P=0.0007) were significantly decreased 131 in subjects with brown fat, suggesting potential roles for brown adipose beyond direct regulation 132 of lipid and glucose metabolism (Extended Data Table 5 ). In summary, our data support an 133 important role for brown fat in mitigating metabolic disease and its cardiovascular sequelae, 134 particularly in obese individuals. 135
Thermogenic fat promotes energy expenditure, and there is increasing evidence that this 136 tissue plays roles in metabolism beyond thermogenesis itself 20,21,22 . While thermogenesis clearly 137 modulates glucose and lipid metabolism, an association between thermogenic fat and blood 138 pressure has not been described until now. Furthermore, transcriptomic profiling indicates that 139 murine beige fat, as opposed to developmentally pre-formed brown fat, closely approximates 140 the inducible brown fat detected by PET/CT in adult humans 23 . We therefore used adipocyte-141 specific PRDM16 knockout (Adipo-PRDM16 KO) mice (Extended Data Fig. 4a, b , and c) with 142 an ablation of beige fat function to investigate the potential link between thermogenic fat and 143 blood pressure control 24 . Interestingly, a previous genome-wide association study demonstrated 144 an association between a coding SNP in exon 9 of PRDM16 (leading to the missense mutation 145 Pro633Leu) and hypertension in humans 25 . 146
Adipo-PRDM16 KO animals were implanted with radiotelemetric devices to monitor 147 blood pressure over a three-week period (Fig. 3a) . Our studies were conducted in 11 to 14-148
week-old mice on a standard chow diet, and body weight was equivalent between genotypes 149 throughout the study (Extended Data Fig. 4d ). Significant increases in systolic (difference 150 between means 3.6 mmHg; 95% CI 0.9-6.4, P=0.0102), diastolic (difference between means 151 4.2 mmHg; 95% CI 1.2-7.2, P=0.0071), mean arterial blood pressure (difference between 152 means 4.0 mmHg; 95% CI 1.8-6.3, P=0.0007) and heart rate (difference between means 18 153 bpm, 95% CI 3-33, P=0.0202) were apparent in KO animals versus controls ( Fig. 3a and  154 Extended Data Table 6 ). After adjustment for heart rate, genotype remained independently 155 associated with increased systolic (difference between means 2.8 mmHg; 95% CI 0.2-5.5, 156 P=0.0378), diastolic (difference between means 3.3 mmHg; 95% CI 0.4-6.2, P=0.0281) and 157 mean arterial blood pressure (difference between means 3.3 mmHg; 95% CI 1.0-5.6, 158 P=0.0052) (Extended Data Table. 7) . 159
There were no significant differences in heart weight, wall thickness, cardiac function or cardiac 160 tissue histology, indicating that neither cardiac morphology nor function were responsible for the 161 observed differences in systemic blood pressure ( Fig. 3b and Extended Data Fig. 5a ). We thus 162 explored resistance vasculature morphology and function. By using the pressure myograph 163 system, second order mesenteric arteries isolated from Adipo-PRDM16 KO mice (after 164 dissecting off all perivascular fat) demonstrated an increased contractile response specifically to 165 angiotensin II, with no significant differences in response to acetylcholine or phenylephrine ( Fig.  166   3c) . Additionally, vasodilation in response to a stepwise increase in flow was significantly 167 decreased in Adipo-PRDM16 KO mice while myogenic tone induced by a stepwise increase in 168 pressure did not show a difference between the genotypes (Extended Data Fig. 5b) . 169
Histological analysis evidenced no apparent structural differences ( Fig. 3d ). There were no 170 significant differences in plasma levels of angiotensinogen ( Fig. 3e ) or expression of 171 angiotensin receptors in the mesenteric arteries ( Fig. 3f) . In summary, ablation of beige fat 172 function in mice leads to an increased sensitivity of resistance arteries to angiotensin II, 173 contributing to elevated systemic blood pressure.
9
Obesity is a major contributor to metabolic and cardiovascular disease, and 48.9% of 175
American adults are predicted to be obese by 2030 26 . With limited effective therapies available, 176 thermogenic fat has been implicated as a potential therapeutic target for obesity and metabolic 177 disease 27 . In healthy adults, cold stimulation of brown fat increases energy expenditure and 178 improves systemic glucose utilization, fatty acid oxidation, and insulin sensitivity 28, 29, 30, 31 . This 179 observation is consistent with animal models, where transplantation of thermogenic adipose 180 tissue mass improved glucose and triglyceride metabolism, while genetic ablation of 181 thermogenic fat had the opposite effect 3,32,33 . The effects of thermogenic adipose tissue on 182 cardiometabolic health and obesity-associated diseases in humans, however, have been largely 183 unexplored until now. 184
Our study illustrates that individuals with thermogenic fat on 18 F-FDG PET/CT have 185 significantly improved metabolic profiles. This effect is not only limited to diabetes, but extends 186 to coronary artery disease, congestive heart failure and hypertension. Furthermore, the effects 187 of brown fat on metabolic and cardiovascular disease are most pronounced among individuals 188 with elevated BMI. While obesity is generally associated with decreased brown fat function 34 , 189 those obese individuals who retain brown fat activity appear to be protected against conditions 190 linked to excess weight. This notion further supports the potential of brown fat as a therapeutic 191 target beyond weight loss itself, but as a means to uncouple obesity from disease. 192
The reduction in the prevalence of hypertension associated with thermogenic fat was of 193 particular interest to us, because this cannot be directly explained by improvements in glucose 194 and lipid metabolism. Our studies in a mouse model lacking beige fat identified changes in 195 sensitivity to angiotensin II in the peripheral resistance vasculature as a potential underlying 196 physiological mechanism. Thermogenic fat secretes a number of endocrine factors that can 197 affect a wide variety of tissues, and ongoing research is focused on elucidating the downstream 198 effectors of these signals. Our work points towards a novel molecular signal linking adipose 199 tissue phenotype to blood pressure control, and may be the first step in elucidating a 200 mechanistic link between brown fat and hypertension. 201
Our study raises a number of questions regarding brown fat development and function in 202 humans. Variability in brown fat prevalence and activity suggests a possible genetic determinant 203 of its biology. Consistent with this, our understanding of genetics as a contributor to type II 204 diabetes development has evolved significantly 35 . It is likely then that genetic factors 205 contributing to brown fat development and activity may affect the pathogenesis of type II 206 diabetes and metabolic syndrome. In our study, brown fat was associated with improved health 207 across several organ systems. As an example, individuals without brown fat exhibited higher 208 leukocyte counts, and elevated white blood cell counts are an established risk factor for 209 coronary artery disease 36,37,38 . Decreased leukocyte counts in individuals with brown fat could, in 210 part, explain the lower prevalence of coronary artery disease among these subjects. Our work 211 highlights the need to determine the extent of brown fat's effects on other organs and roles in 212 systemic metabolism. 213
The major strength of our study is the size of the dataset, the largest we are aware of, 214 and the linkage to electronic health records. This allowed us to comprehensively examine 215 associations between brown fat and a wide variety of data. There are, however, a number of 216 limitations that need to be acknowledged, mainly pertaining to the retrospective design and 217 analysis of data from a cancer population. First, identification of brown fat relies on 18 F-FDG 218 PET/CT and consistent reporting. Our manual review of brown fat reporting over an entire year, 219 as well as a consistent brown fat prevalence over the study period, support the reliability of 220 reporting in this study. Furthermore, 18 F-FDG PET/CT without prior cold stimulation tends to 221 underestimate brown fat prevalence, which may have impacted our classification. In the 222 absence of broadly applicable screening methods or biomarkers for brown fat, the application of 223 prevalence as measured by 18 F-FDG PET/CT, the effect of cancer is still poorly understood. We 226 have thus adjusted our analysis to accommodate the potential influence of cancer type and 227
stage. 228
In our study, we investigated and confirmed new clinical findings linking thermogenic 229 adipose tissue and improvements in metabolic health using an established mouse model. These 230 findings will have the potential to enable translation of animal findings into viable human 231 therapies. Our study highlights the therapeutic potential of modulating brown fat in humans to 232 combat the escalating obesity crisis. 233 234
Online Methods 235

Study Design and Participants 236
This retrospective case-control study followed institutional guidelines and was approved by the 237 regions corresponding to adipose tissue on CT, and it is standard practice at MSKCC to 246 document these signatures in all reports. We searched all 18 F-FDG PET/CT reports for the 247 terms "brown fat" or "brown adipose". Patients were then categorized by the presence or 248 absence of brown fat reporting. For each subject in both groups, an index scan was designated 249 as follows: in patients with brown adipose tissue reported on at least one 18 F-FDG PET/CT 250 scan, the first scan that reported brown fat was defined as the index scan. In patients without 251 brown fat on any scan, the first 18 F-FDG PET/CT scan served as the index scan ( Fig. 1) . 252
253
Data collection 254
We obtained average outdoor temperatures in New York City, measured in Central Park, for the 255 months of scans from the U.S. National Weather Service. All patient data including 256 demographics and self-reported race and ethnicity were collected from institutional electronic 257 health records (EHR). Diagnoses listed up to one year after the time (month and year) of the 258 index scan were identified using diagnostic codes from the International Classification of 259
Diseases, 9th and 10th Revisions (ICD-9 and ICD-10) ( Supplementary Data Table 1) . 260 13 Laboratory values were recorded from the EHR if these values were first measured within three 261 months (complete blood counts) or one year (lipid levels) of the index scan date. In case of 262 multiple data points available, the one closest to the index scan was used for analysis. Blood 263 glucose was routinely measured on the day of scanning. Complete blood counts from patients 264 with hematological malignancies were excluded from analysis. With the exception of fasting 265 blood glucose, measurement of blood values was not coupled to 18 F-FDG PET/CT scans. Data 266 completeness was assessed for all blood values, and available data was analyzed using 267 complete case analysis (Extended Data Table 5 ). Data completeness ranged from 11.7% (low-268 density lipoproteins) to 98.1% (glucose). 269 270
Propensity Score Matching and Identification of Study Cohort 271
To identify the study cohort, patients with reported brown fat were matched to patients without 272 reported brown fat using propensity score matching. Propensity scores were estimated using a 273 non-parsimonious multivariable logistic-regression model with brown adipose tissue status 274 (presence or absence) as the dependent variable and age, sex, BMI, and temperature at time of 275 scan as covariates. Matching was performed using a 1:1 protocol without replacement (greedy-276 matching algorithm), a caliper width of 0.2 and the variable sex was set to be exactly matched. 277
We used standardized difference means to assess balance before and after matching 278 Fig. 3 ). Matching was conducted in SAS version 9.4 (SAS Institute, Cary, NC) 279 using the psmatch function. 280
281
Outcomes 282 ICD-9/10 diagnoses extracted from EHRs were used to examine associations between brown 283 fat and cardiometabolic health defined as the prevalence of type II diabetes, dyslipidemia, 284 hypertension, coronary artery disease, congestive heart failure and cerebrovascular disease. All 285 ICD-9/10 codes used to assign disease categories are listed in Supplementary Data Table 1 . 286
Data Analysis 288
We first assessed the correlation between brown fat and age, outdoor temperature in the month 289 of the 18 F-FDG PET/CT index scan and BMI. For age and BMI, a one-phase exponential decay 290 curve was modeled and the correlation was assessed by calculating Spearman's rank 291 correlation coefficient. For temperature, a linear regression line was calculated and the 292 correlation was assessed by calculating Spearman's rank correlation coefficient. Prevalence of 293 brown fat in men and women was compared using chi-squared test. Brown adipose status 294 (either present or absent) and prevalence of cardiometabolic diseases were compared using 295 chi-squared tests. 296
Next, we assessed whether brown fat status was an independent predictor of cardiovascular 297 disease by using multivariable logistic regression analysis. The dependent variable in this 298 analysis was the respective cardiometabolic disease and brown fat status (presence or 299 absence) was the independent variable. To adjust for potential confounders that were selected 300 based on previous publications, we controlled for the following variables: age, sex, BMI, outdoor 301 temperature in Central Park in the month of the index scan, smoking status, race, ethnicity, 302 family history of cardiovascular disease, beta blocker use, cancer site, and cancer stage. 303
Smoking was coded as a categorical variable with 4 levels (current smoker, previous smoker, 304 never smoker, unknown smoking status). Race was a categorical variable with 4 levels: 305
Caucasian, African-American, Asian and other (e.g. Pacific-Islanders, unknown). Ethnicity was a 306 categorical variable with three levels: Hispanic, Non-Hispanic and Unknown. Cancer stage was 307 a 6 level categorical variable consisting of Stages I-IV, not applicable (e.g. hematologic 308 malignancies, benign tumors), and unknown cancer stage. Cancer site was recorded according 309 to ICD 0 Site Codes and included 14 categories: C00-C14, C15-C26, C30-C39, C40-C41, C42, 310 15 C43-C44, C45-C49, C50-C58, C60-C63, C64-C68, C69-C72, C73-C75, C76-C80 and 311 other/unknown. Results were reported as odds ratio and 95% confidence interval. 312
Cardiometabolic diseases that were independently associated with brown fat status were further 313 stratified by BMI categories (normal weight, defined as BMI <25km/m 2 ; overweight, defined as 314 BMI 25.0 -30.0 kg/m 2 ; obese, defined as BMI >30.0 kg/m 2 ). Comparison between individuals 315 with and without brown fat in the respective category were performed using the multivariable 316 logistic expression model outlined above to assess whether observed differences were 317 statistically significant. For the comparison of laboratory values, a Student's t-test was 318 performed. To compare associations between brown fat status, BMI and available lab values, a 319 least squares linear regression line was constructed, stratified by brown status. All p-values are 320 two-tailed, and values less than 0.05 were considered statistically significant. 321
322
Animal Experiments 323
Animal care and experimentation were performed according to procedures approved by the 324
Institutional Animal Care and Use Committee at the Rockefeller University. The Adipo-PRDM16 325 KO mice were generated by breeding Prdm16lox/lox mice with Adiponectin-cre mice (provided 326 by Dr. Evan Rosen, backcrossed to a C57BL/6J background) 24 Blood pressure was measured by implantable radio transmitters as previously described 40 . 341
Briefly, male mice at age 11-14 weeks were housed in pairs. Prior to implantation, the animals 342 Mice were anaesthetized with isoflurane under continuous monitoring and placed on a heating 402 pad of a recording stage connected to a Vevo 2100 ultrasound machine. The anterior chest wall 403 was shaved, ultrasound gel was applied and electrodes were connected to each limb to 404 simultaneously record an electrocardiogram. Two-dimensional (short axis-guided) M-mode and 405 B-mode measurements (at the level of the papillary muscles) were taken using an 18-32 MHz 406 MS400. For analysis, at least three measurements were averaged; measurements within the 407 same HR interval (450 ± 50 bpm) were used for analysis. 408 409
Pressure myography 410
Mesenteric arteries were collected from 18-week-old male mice, as described above. Second Mann-Whitney U test or two-way ANOVA based on data distribution and as indicated. All p-433 values are two-tailed, and values less than 0.05 were considered statistically significant. 434 of brown fat was higher in females compared with males. Groups were compared by chi-square 570 test, P-value is two-tailed. e, Brown fat prevalence was inversely correlated with age and 571 followed a one-phase decay. Spearman's rank correlation coefficient was calculated to assess 572 the correlation between brown fat prevalence and age, P-value is two-tailed. f, Brown fat 573 prevalence, based on 18 
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